Special Episode: As a Vaccine Rolls-Out, What’s Next?

Special Episode: As a Vaccine Rolls-Out, What’s Next?

Although the first COVID-19 vaccine has now begun distribution in the U.S., the country still faces alarming numbers of new cases. We dive into the logistics of mass vaccination.

Jaksot(1511)

Michael Zezas: Should Investors Prepare for No Stimulus?

Michael Zezas: Should Investors Prepare for No Stimulus?

With mixed signals coming from the White House and Congress, should investors be concerned about no further stimulus? Why there may still be good news.

7 Loka 20202min

Mike Wilson: Rate Scare on Deck?

Mike Wilson: Rate Scare on Deck?

With a U.S. fiscal stimulus deal looking more likely, the risk of long-term interest rates moving higher has now increased—a shift that could benefit recovery stocks.

5 Loka 20203min

Andrew Sheets: How Will Markets React to a Workable Vaccine?

Andrew Sheets: How Will Markets React to a Workable Vaccine?

For markets, a vaccine may be the most significant sign the world may return to a more normal future. But what are markets pricing in currently?

2 Loka 20202min

Special Episode: COVID-19 Vaccine - Trials and Tribulations

Special Episode: COVID-19 Vaccine - Trials and Tribulations

COVID-19 vaccines are navigating through the last stage of clinical trials, but hurdles still lie ahead for efficacy, distribution and FDA approval.

1 Loka 20209min

Michael Zezas: It’s the Results That Count

Michael Zezas: It’s the Results That Count

How will markets react if final U.S. election results take days or weeks? Head of U.S. Public Policy Research Michael Zezas shares advice for investors.

30 Syys 20202min

Mike Wilson: Near-term Correction; Long-term Recovery?

Mike Wilson: Near-term Correction; Long-term Recovery?

The recent correction may have been inevitable given rising risks for fiscal stimulus, a potential COVID-19 second wave and the upcoming election. But a resolution to these hurdles may also be possible longer-term.

28 Syys 20203min

Andrew Sheets: Four Reasons to Remain Patient

Andrew Sheets: Four Reasons to Remain Patient

Despite a needed correction in recent weeks, a suite of significant risks still hangs over U.S. markets. Chief Cross-Asset Strategist Andrew Sheets explains.

25 Syys 20202min

Michael Zezas: Unlikely Paths to Stimulus May Interest Investors

Michael Zezas: Unlikely Paths to Stimulus May Interest Investors

As hopes for an additional stimulus package wane in the run-up to the U.S. elections, some of the less likely paths to a deal may provide a way out of the current correction. Michael Zezas, Head of U.S. Public Policy Research, explains.

24 Syys 20202min

Suosittua kategoriassa Liike-elämä ja talous

sijotuskasti
mimmit-sijoittaa
psykopodiaa-podcast
rss-rahapodi
lakicast
rss-rahamania
herrasmieshakkerit
rss-neuvottelija-sami-miettinen
ostan-asuntoja-podcast
pomojen-suusta
rss-lahtijat
oppimisen-psykologia
syo-nuku-saasta
rss-myyntipodi
rss-startup-ministerio
rss-bisnesta-bebeja
rss-myynti-ei-ole-kirosana
rss-inderes-femme
rss-yritys-ja-erehdys
rss-rahataito-podcast